Evidence map›Paper›PMID 37884514›Full record

ArticleBlood cancer journal2023

Proteomics uncovers molecular features for relapse risk stratification in patients with diffuse large B-cell lymphoma.

Maja Ludvigsen, Amanda Jessica Campbell, Marie Beck Enemark, Trine Engelbrecht Hybel, Marja-Liisa Karjalainen-Lindsberg, Klaus Beiske, Mette Bjerre, Lars Møller Pedersen, Harald Holte, Sirpa Leppä and 2 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Maja LudvigsenDepartment of Hematology, Aarhus University Hospital, Aarhus, Denmark. majlud@rm.dk.ORCID 0000-0001-5089-3271
Amanda Jessica CampbellDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.ORCID 0009-0003-3582-3728
Marie Beck EnemarkDepartment of Hematology, Aarhus University Hospital, Aarhus, Denmark.
Trine Engelbrecht HybelDepartment of Hematology, Aarhus University Hospital, Aarhus, Denmark.
Marja-Liisa Karjalainen-LindsbergDepartment of Pathology, Helsinki University Hospital, Helsinki, Finland.
Klaus BeiskeDepartment of Pathology, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway.
Mette BjerreMedical/Steno Aarhus Research Laboratory, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Lars Møller PedersenZealand University Hospital, Roskilde, Denmark.
Harald HolteDepartment of Oncology, Oslo University Hospital, Oslo, Norway.
Sirpa LeppäResearch Program Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-8265-511X
Judit Meszaros Jørgensen *Department of Hematology, Aarhus University Hospital, Aarhus, Denmark.
Bent Honoré *Department of Biomedicine, Aarhus University, Aarhus, Denmark. bh@biomed.au.dk.ORCID 0000-0002-3459-7429

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Lymphoma, Large B-Cell, DiffuseProteomicsAntineoplastic Combined Chemotherapy ProtocolsHumansNeoplasm Recurrence, LocalRisk AssessmentRituximabRituximab

Identifiers

PMID37884514
PMCPMC10603067

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.